BACE1 and Alzheimer disease: BACE1 inhibitors have demonstrated reduction of Aβ in mild to moderate AD [14], suggesting that clearance, although possibly impaired at that stage of AD, is adequate to achieve Aβ reduction acutely, following from BACE1 inhibition [105].